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Innate Immune Basis for Rift Valley 
Fever Susceptibility in Mouse 
Models
Rashida Lathan1,2, Dominique Simon-Chazottes1,2, Grégory Jouvion3, Ophélie Godon4,5, 
Marie Malissen6,7,8, Marie Flamand9, Pierre Bruhns  4,5 & Jean-Jacques Panthier1,2
Rift Valley fever virus (RVFV) leads to varied clinical manifestations in animals and in humans that 
range from moderate fever to fatal illness, suggesting that host immune responses are important 
determinants of the disease severity. We investigated the immune basis for the extreme susceptibility 
of MBT/Pas mice that die with mild to acute hepatitis by day 3 post-infection compared to more 
resistant BALB/cByJ mice that survive up to a week longer. Lower levels of neutrophils observed 
in the bone marrow and blood of infected MBT/Pas mice are unlikely to be causative of increased 
RVFV susceptibility as constitutive neutropenia in specific mutant mice did not change survival 
outcome. However, whereas MBT/Pas mice mounted an earlier inflammatory response accompanied 
by higher amounts of interferon (IFN)-α in the serum compared to BALB/cByJ mice, they failed to 
prevent high viral antigen load. Several immunological alterations were uncovered in infected MBT/
Pas mice compared to BALB/cByJ mice, including low levels of leukocytes that expressed type I IFN 
receptor subunit 1 (IFNAR1) in the blood, spleen and liver, delayed leukocyte activation and decreased 
percentage of IFN-γ-producing leukocytes in the blood. These observations are consistent with the 
complex mode of inheritance of RVFV susceptibility in genetic studies.
Rift Valley Fever (RVF) is caused by an emerging arbovirus endemic in sub-Saharan African countries. RVF virus 
(RVFV) may spread as a result of the movement of infected animals. Epizootics are identified by a large number 
of mass abortions, perinatal mortality and hemorrhagic syndrome in livestock1. In a minority of infected humans, 
the disease progresses from a self-limiting febrile illness to severe hepatitis with hemorrhagic manifestations, 
encephalitis, and ocular lesions2, 3. The RVFV infection in laboratory rodents mimics many aspects of the pathol-
ogy in humans4, 5. In particular, infection of BALB/c mice recapitulates the hepatitis and encephalitis observed in 
human disease6. The mouse liver is an early and dominant target of RVFV, with extensive damage to hepatocytes 
via apoptosis. Mice that survived this early hepatic phase develop infection in the brain. Lymphoid tissues are 
also affected by RVFV. The main lymphoid lesion is lymphocyte apoptosis (lymphocytolysis) as observed in the 
thymus, spleen, lymph nodes, and mucosa-associated lymphoid tissues6, 7. Moreover, a spectrum of pathogenic 
phenotypes can be observed in inbred mice, as in humans6, 8–10, suggesting that host genetic factors are important 
determinants of the susceptibility to RVF disease. We have previously shown that wild-derived inbred MBT/Pas 
(MBT) mice are highly susceptible to infection with the virulent RVFV ZH548 and Kenya 98 strains in compari-
son to more resistant BALB/cByJ (BALB/c) mice11. We have demonstrated that the susceptibility in MBT mice is a 
complex trait, inherited in a multifactorial manner12. Three different quantitative trait loci (QTLs) have been asso-
ciated with the severity of the disease. The effects of these QTLs are accumulative yet modest, as they explain only 
8.3% of the difference in susceptibility between BALB/c and MBT mice. This implies that susceptibility is a result 
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of several independent mechanisms controlled by many DNA variants with minor effects12. Mouse embryonic 
fibroblasts (MEFs) derived from MBT mice elicited a delayed and partial type I IFN response when infected with 
RVFV11. This result suggested that MBT mice fail to induce, in due course, a complete innate immune response 
which contributes to their susceptibility to RVF11.
Innate immune cells, and in particular cell subsets such as dendritic cells (DCs), natural killer (NK) cells, and 
neutrophils play crucial roles in early antiviral defense. Though DCs are not involved in early pathogen clearance, 
they are potent antigen-presenting cells and are a source of viral protective type I interferons (IFNs)13. Type I 
IFNs response is precipitated through the IFN-α and -β (IFNAR1/2) heterodimeric receptor, and the downstream 
induction of IFN-stimulated genes (ISGs) is responsible for an effective antiviral defense. It has been suggested 
that the cell surface expression level of IFNAR1 is a determining factor for specific cellular responses14. NK cells 
are early viral sensors that lyse virus-infected cells, and regulate the adaptive immune response by secreting 
cytokines such as IFN-γ15. Defects in NK cell activity, such as decreased production of IFN-γ, could render mice 
more susceptible to viral infection16. Neutrophils are abundant, highly motile, and efficient phagocytic immune 
cells. It has been suggested that the key to their active role during infection in mice is an ability to be replen-
ished through rapid proliferation within the bone marrow17. Though neutrophils are more commonly associated 
with defense against bacterial and fungal pathogens, they have been demonstrated to play protective roles in 
mice against influenza virus during the initial stages of the innate immune response in limiting virus replication 
and spread, and lethality18. Despite their individual contributory roles in viral protection, innate immune cells 
act rarely in isolation, as crosstalk and interaction characterize innate immune protection in mammalian hosts. 
DCs, NK cells, and neutrophils have all been reported to interact during viral resistance and collectively create a 
microenvironment of IFNs, cytokines, and cell activation required in viral clearance19.
RVFV is sensitive to the action of type I IFNs, but it has evolved a comprehensive mechanism to limit their 
effects by maintaining the promoter of IFN-β (Ifnb1) gene in a repressed state20, 21 (see recent review in ref. 22). 
Several studies provided evidence that RVFV evades the innate immune response, thus facilitating infection of 
hepatic cells at days 3–5 post infection9, 10. In this context, the role of innate immune cells in RVFV infection is 
not understood.
The study described here was developed with the intent to establish the contributions of innate immune cells 
in the susceptible MBT and more resistant BALB/c mice after infection with virulent wild type RVFV. We inves-
tigated the innate immune cell population fluctuations within the organ compartments, including those of high 
viral antigen load, the blood, spleen and liver, and evaluated the expression of viral sensing components (IFN-α 
and -β receptor 1 [IFNAR1]), and migratory and activation markers (P-selectin glycoprotein ligand-1 [PSGL-1], 
and IFN-γ). Herein, we present evidence that RVFV-infected MBT mice display a number of immune-related 
defects in the multi-faceted antiviral response.
Results
Host genetics determines degree of susceptibility to RVFV-induced hepatitis. Groups of 10 to 
20 mice from six inbred strains (C57BL/6, BALB/c, PWK/Pas, SEG/Pas, 129/SvPas, and MBT) were infected by 
RVFV to create mouse models to define the inherited determinants of antiviral host defense in susceptible and 
resistant mice. Mice were monitored for survival time and clinical outcome. Results uncovered extreme sur-
vival phenotypes between a highly susceptible wild-derived strain, MBT, and a more resistant classical laboratory 
strain, BALB/c11, 23. BALB/c mice died at a median of 8 days, and 3 out of 28 (11%) survived past 12 days post 
infection with 100 plaque-forming units (PFU) of RVFV strain ZH548. By contrast, 30 out of 30 (100%) MBT 
mice died at a median of 3 days, and none survived past 6 days post infection (Fig. 1a). In addition, BALB/c mice 
underwent a complete spectrum of symptoms that included a slow gait, clinical signs of neuropathology with 
lower limb paralysis and/or head tilting and spinning, and severe lethargy. In contrast, the clinical symptoms of 
MBT mice before death were acute with the majority of animals displaying no physical representation of disease, 
and only 27% displaying a slow gait within 24 h preceding death (Fig. 1b).
We have previously reported that infectious RVFV was detected as early as one day post infection in sera of 
MBT mice and was undetectable in BALB/c mice at this timepoint. Furthermore, 3 days post infection, RVFV 
titers were shown to be three logs greater in MBT sera compared to BALB/c sera11. Since RVFV is known to 
induce acute-onset hepatitis in mice, concomitant with a rise in serum viral titer6, liver pathology of BALB/c and 
MBT strains was investigated. Serum levels of two liver enzymes, alanine aminotransferase (ALT) and aspartate 
transaminase (AST), were significantly elevated in MBT mice on day 3 post infection (median values 2844 and 
3032 U/L, respectively), by comparison with uninfected controls (80 and 292 U/L, respectively; Mann-Whitney 
U test, p < 0.01 for both), suggesting an early onset of liver dysfunction. This phenomenon was not evident in 
BALB/c mice at day 3 post infection, with only mildy elevated ALT levels (510 U/L compared with 98 U/L in 
uninfected controls; Mann-Whitney U test, P < 0.01). However, in BALB/c mice, ALT and AST levels peaked on 
day 4 post infection (median values 9180 and 5280 U/L, respectively) and subsequently decreased, as reported 
previously6. Comparative histological analyses of livers from uninfected and day 3 infected BALB/c and MBT 
mice showed minimal to mild multifocal hepatitis, characterized by randomly distributed inflammatory foci 
containing mostly fragmented neutrophils in infected BALB/c and MBT mice. In these foci, necrotic and apop-
totic hepatocytes could also be detected as well as cell debris. At the periphery of the lesions, acidophilic inclusion 
bodies could be identified in the nucleus of remaining hepatocytes (Fig. 2a,b,d and e). Immunochemistry with 
antibodies against the RVFV N protein revealed no differences in the distribution and profile of N-positive cells 
between BALB/c and MBT mice (Fig. 2c and f). The density of infected cells was indeed highly variable depend-
ing on liver sections, and on individual mice irrespective of the inbred strain. Altogether, survival, viral detection 
in blood, liver chemistry, and liver pathology indicate a neutrophil associated viral hepatitis with disparate sur-
vival time between the inbred strains, BALB/c and MBT.
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Higher viral antigen loads in the blood, spleen and liver of MBT mice. We assessed levels of RVFV 
nucleoprotein (N) antigen in single-cell suspensions of the brain, blood, spleen, and liver from BALB/c and 
MBT mice on days 1–3 post RVFV infection using flow cytometric analysis. Virtually no viral antigen-positive 
cells were detected in the brain of BALB/c and MBT mice in that period (not shown). In the blood, the average 
Figure 1. Host genetics contributes to susceptibility and symptoms of RVF disease. (a) Survival curves of 
BALB/c (n = 28) and MBT (n = 30) mice infected intraperitoneally with 102 PFU RVFV strain ZH548. (b) 
Trajectory of symptoms of these mice as observed daily, preceding death. Mantel-Cox’s Logrank test was 
performed to assess survival curve differences. ***P < 0.001.
Figure 2. Histopathological analysis from non-infected and RVFV-infected BALB/c and MBT mice at day 3 
post infection. (a,b,d,e) Hematoxylin and eosin (HE) staining of liver: arrowheads indicate lesions with necrotic 
and apoptotic hepatocytes, and neutrophil infiltrate (insets: intra-nuclear inclusion bodies with margination of 
nuclear chromatin, arrows). (c,f) Immunohistochemical detection of the N protein of RVFV.
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percentages of viral antigen-positive cells were significantly higher on days 2 and 3 post infection in MBT mice 
compared to BALB/c mice (Fig. 3a). In the spleen and liver, higher levels of viral antigen-positive cells were 
detected at day 3 post infection in MBT mice when compared to BALB/c mice (Fig. 3b and c). The liver exhibited 
the highest percentages of viral antigen-positive cells at day 3 post infection (Fig. 3c, and Supplementary Fig. 1).
The primary lesion in the spleen of RVFV-infected mice is lymphocytolysis, as reported previously6. We 
assessed the spleen for markers of cell viability and apoptosis comparing mock-treated or RVFV-infected BALB/c 
and MBT mice. Results revealed a high percentage of viable cells on all days within the spleen of infected BALB/c 
mice, similar to levels in mock-treated BALB/c and MBT controls. By contrast, cell viability was greatly reduced 
in the spleen of infected MBT mice (Fig. 3d). This decreased cell viability was not due to caspase-3-dependent 
apoptosis (Supplementary Fig. 2). These data suggest increased cell death in the MBT spleen in association with 
increased viral antigen load.
Differential distribution of innate immune cells in BALB/c and MBT mice. To assess the impact 
of RVFV infection on innate immune cell frequency and subset distribution, a comprehensive flow cytometric 
profiling of key innate immune cells in the blood, spleen, liver and bone marrow of mock- and RVFV-infected 
BALB/c and MBT mice was performed on days 0–3. In BALB/c mice, results revealed a drop in circulating 
CD45-positive leukocytes starting with the infection (Fig. 4a). A steady decrease in the leukocyte levels was 
also registered in the liver and bone marrow post infection. The counts of the leukocytes in the liver and bone 
marrow of BALB/c mice were at their lowest levels at day 3 after infection (Fig. 4a). The overall leukocyte levels 
in the spleen did not change during the investigated period. In MBT mice, the leukocyte levels in the blood and 
bone marrow were already lower before infection compared to non-infected BALB/c mice (Fig. 4a). Interestingly, 
circulating MBT leukocytes and leukocytes in the spleen and liver were maintained at comparable levels as in 
BALB/c mice, despite lower levels of leukocytes originating from MBT bone marrow at days 0–2 post infection. 
Data from the bone marrow also suggests that the systemic deficit in MBT leukocytes was remedied at day 3 post 
infection when MBT leukocyte levels surpassed that of BALB/c (Fig. 4a).
To identify the key cell subsets of leukocytes affected after infection, we narrowed the experimental focus to 
evaluate organs with high viral load, the spleen and liver, and surveyed numerous cells at the stage when the aver-
age MBT mouse was within 24 hours of succumbing to RVFV-induced fatality, at day 3 post infection. We profiled 
for dendritic cells (DCs), natural killer (NK) cells, neutrophils, macrophages, and B-cells. We also evaluated for 
the potential of early adaptive cell response by assessing surface CD4 and CD8 T cell expression (Supplementary 
Fig. 3). Experimental analysis identified three cell subsets, DCs, NK cells, and neutrophils in the spleen, as signif-
icantly lower in MBT mice when compared to the more resistant BALB/c mice (Mann-Whitney U test, P < 0.05) 
(Fig. 4b, data in liver not shown). These cell types subsequently became the focus for our comprehensive study.
Figure 3. Higher viral antigen load correlates with higher cell death in the spleen of MBT mice. (a–c) Flow 
cytometric analysis for the N viral nucleoprotein (N-antigen, N-ag) within the blood (a), spleen (b), and liver 
(c) cells from BALB/c (n = 5/day) and MBT (n = 5/day) mice on days 1–3 post RVFV infection. (d) Percentages 
of viable cells in the spleen of RVFV-infected BALB/c and MBT mice using flow cytometry (n = 5 mice/strain/
timepoint). Data are represented as mean ± SEM. Two-way ANOVA was used to test differences between 
means. *P < 0.05, **P < 0.01, ***P < 0.001.
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Informative data were obtained in the spleen of MBT mice where DC levels, already low before infection when 
compared with BALB/c mice, decreased further at day 1 post infection (Fig. 4b). Similarly, NK cell levels dropped 
on days 1 and 2 post infection in MBT mice to reach very low values (Fig. 4b). The most striking observation was 
the rise in neutrophils at day 2 post infection, which occurred earlier than in BALB/c mice, followed by a sudden 
drop at day 3 post infection which did not happen in BALB/c mice (Fig. 4b). To best recognize cell subtype con-
tribution differentiating BALB/c and MBT strains, principal component (PCA) and linear discriminant (LDA) 
analyses were performed on innate cell profiles in the spleen at days 0–3 post infection. LDA analysis ranked 
neutrophils as having most impact starting on day 2 and persisting until day 3 post infection on the dissimilarity 
between infected BALB/c and MBT mice (Fig. 4c). Collectively, flow cytometric profiling of key innate immune 
cells in MBT mice argues for abrupt and large increases in splenic neutrophils at day 2 post infection and in bone 
marrow-derived leukocytes on day 3 post infection. These increases were not observed in BALB/c mice. During 
the investigated period, DCs remained at very low levels in MBT spleen, while splenic NK cells even reduced to 
attain lower levels than in BALB/c.
Exhaustion of neutrophils in the blood and bone marrow of MBT mice. Flow cytometric profil-
ing showed that circulating neutrophil levels were similar in mock-infected and on day 1 post infection in both 
mouse strains, but they became lower on days 2 and 3 post infection in MBT strain when compared to BALB/c 
strain (Fig. 5a). In the BALB/c bone marrow, neutrophil levels declined on day 1 post infection and remained at 
steady levels afterwards. By contrast, an increase in neutrophil levels was observed at day 1 post infection in MBT 
bone marrow followed by a progressive decline (Fig. 5a). In the liver, a modest increase in neutrophil level was 
observed in BALB/c mice on day 2 post infection. By contrast, a steady and steep increase in neutrophil levels was 
observed in the MBT liver (Fig. 5a). Neutrophil levels dropped in the MBT blood and bone marrow even more 
severely between days 1 and 3 post infection compared to BALB/c mice (Fig. 5a). These results suggest that, in 
MBT mice, neutrophils accumulate progressively in the liver where the viral antigen load is the highest at day 3 
post infection, at the expense of the blood, spleen, and bone marrow.
We investigated neutrophil activation by measurement of intracellular IFN-γ in the blood, spleen and liver 
at day 3 post infection. IFN-γ expression trended lower in circulating and splenic neutrophils in MBT mice 
Figure 4. Changes in the percentages of innate immune cells in RVFV-infected BALB/c and MBT mice. (a) 
A comprehensive flow cytometric profiling of leukocytes defined as positive for CD45 in the blood, spleen, 
liver and bone marrow of RVFV-infected BALB/c and MBT mice on days 0–3 post infection. (b) Percentages 
of key innate immune cell populations, DCs (CD45+, CD11c+), natural killer (NK) cells (CD45+, CD335+), 
and neutrophils (CD45+, Ly6C/Ly6G+), after infection with RVFV in the spleen of BALB/c and MBT mice. 
(c) Linear discriminant (LDA) analyses ranks neutrophils, as having the greatest impact on the dissimilarity 
between BALB/c and MBT spleen at day 3 post infection. Cytometry experiments were performed twice for 
each time point (n = 5 mice/strain/timepoint). Representative experiments are displayed. Data are represented 
as mean ± SEM. Two-way ANOVA was used to test differences between means. *P values < 0.05, **P < 0.01, 
and ***P < 0.001.
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compared with BALB/c mice, whereas IFN-γ levels in liver neutrophils trended higher in MBT mice compared 
with BALB/c mice (Supplementary Fig. 4).
Another marker of neutrophil activation we exploited is P-selectin glycoprotein ligand-1 (PSGL-1). Its func-
tion is vital during leukocyte recruitment into tissues and its regulation is integral during acute inflammation. 
Slow rolling of leukocytes on the endothelial cells lining venules of the tissues is the earliest observable event 
of this physiological reaction. The initial tethering and rolling of circulating leukocytes is mediated by PSGL-1 
that binds to P-selectin expressed by endothelial cells24. In addition to its tethering function by endothelial cells, 
PSGL-1 can nucleate leukocyte-leukocyte interactions by binding to L-selectin also expressed on the surface of 
circulating leukocytes, thus enabling secondary leukocyte capture25, 26. We measured PSGL-1 levels on circulating 
neutrophils during infection in BALB/c and MBT mice. At day 3 post infection, higher percentages of PSGL-
1-positive neutrophils were observed in MBT compared to BALB/c blood (Fig. 5b), suggesting enhanced tether-
ing and rolling ability of MBT neutrophils to site of inflammation at that time. This conclusion is consistent with 
the increased levels of neutrophils in the liver of MBT mice compared with BALB/c mice at day 3 post infection 
(Fig. 5a).
Neutrophil recruitment was studied after injection of thioglycollate into the peritoneal cavity of BALB/c and 
MBT mice. Similar numbers of neutrophils were observed in the thioglycollate-stimulated peritoneal exudates of 
BALB/c and MBT mice. This suggests that MBT neutrophils do not have higher capacity to be recruited to a site 
of inflammation (Supplementary Fig. 5).
Taken together these data indicate that, after a faster response to the infection, MBT mice sustained lower 
levels of circulating neutrophils than BALB/c mice. To understand if the level of circulating neutrophils is critical 
during RVF disease, we used C57BL/6 mice that carry either null (Gfi1GFP) or hypomorphic (Gfi1Gen) alleles at the 
Gfi1 locus. Homozygous Gfi1GFP/GFP mice show a severe neutropenia and additional defects in the B- and T-cell 
lineages and in the hematopoietic stem cell fraction while heterozygous Gfi1+/GFP littermates are indistinguish-
able from wild type mice27. Homozygous Gfi1Gen/Gen mice are almost deprived of mature neutrophils, but they 
exhibit milder defects on hematopoietic precursors and on the development of lymphoid cells28. Survival curves 
of Gfi1GFP/GFP and Gfi1+/GFP mice on the one hand, and Gfi1Gen/Gen and Gfi1+/+ mice on the other hand did not dif-
fer significantly after infection (Supplementary Fig. 6a and b, respectively). These results suggest that neutrophils 
are not critical during RVF disease.
Expression of type I interferons and their receptor in susceptible MBT mice. Increased 
IFN-α/β response is a key mechanism of innate immunity to protect the host against invading viruses29. We 
assayed IFN-α/β in the serum of mock- and RVFV-infected BALB/c and MBT mice between days 1 and 3 post 
infection. NSs, the major virulence factor of RVFV is known to inhibit the synthesis of Ifnb1 gene encoding 
IFN-β30. Accordingly, IFN-β remained below detection level in sera from infected BALB/c and MBT mice. 
Figure 5. Faster recruitment of neutrophils, and higher PSGL-1 levels in neutrophils at day 3 post infection in 
MBT mice. (a) Flow cytometric profile of neutrophil (CD45+, Ly6C/Ly6G+) populations in the blood, liver, 
and bone marrow of RVFV-infected BALB/c and MBT mice on days 0–3 post infection. Two-way ANOVA 
was used to test differences between means (b) Percentages of PSGL-1-positive circulating neutrophils at day 3 
post infection. Cytometry experiments were performed twice (n = 5 mice/strain/timepoint, unless otherwise 
indicated). Data are represented as mean ± SEM. Mann- Whitney U test was used to compare differences 
between means. *P < 0.05, **P < 0.01, and ***P < 0.001.
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However, significant concentrations of the related interferon-α were measured in BALB/c and MBT mice at 
day 2 post infection, with a stronger IFN-α expression in MBT mice (569 ± 21 pg/ml) compared to BALB/c 
mice (87 ± 87 pg/ml; two-way ANOVA, P < 0.05) (Fig. 6a). No differences between strains were seen at day 3 
post infection (262 ± 137 pg/ml and 471 ± 99 pg/m in BALB/c and MBT mice, respectively; two-way ANOVA, 
P = 0.31) (Fig. 6a). Thus, MBT mice are able to induce rapidly a much stronger IFN-α response than BALB/c 
mice.
The levels of IFN-α and -β receptor 1 (IFNAR1) on the cell’s surface determine the sensitivity of cells to type I 
IFNs and control the magnitude and duration of effect elicited by these cytokines14, 31. We investigated if this viral 
trigger for innate immune defense was functional in MBT mice via measurement of IFNAR1 cell surface expres-
sion. Following infection with RVFV, the percentages of IFNAR1-positive leukocytes increased dramatically in 
the blood, spleen and liver of BALB/c mice (Fig. 6b). By contrast, the IFNAR1-positive leukocyte increases were 
less pronounced in the blood and spleen of MBT mice. In the MBT liver, the increase was also weaker com-
pared to the BALB/c liver, but by day 3 post infection IFNAR1-positive leukocyte levels surpassed levels found in 
BALB/c liver (Fig. 6b).
Collectively, these data indicate that RVFV infection induced an increase in the percentage of leukocytes 
expressing type I IFN receptor 1 in BALB/c mice, potentially strengthening the cellular response to type I IFNs in 
the course of infection. By contrast, a smaller percentage of leukocytes expressed IFNAR1 in MBT mice, suggest-
ing a lower ability to trigger a response to type I IFNs compared to BALB/c mice.
Delayed activation of circulating leukocytes in MBT mice. To further evaluate the activation of 
immune cells in MBT mice and their subsequent capacity to mobilize during RVFV infection, we examined 
IFN-γ production in circulating leukocytes and their surface expression of PSGL-1.
Activation of leukocytes in the blood of BALB/c and MBT mice was evaluated by the production of IFN-γ 
at each day after infection. The IFN-γ-positive leukocyte population increased at day 3 post infection in 
BALB/c blood, indicating that circulating leukocytes were activated at this stage. By contrast, the population of 
IFN-γ-positive leukocytes was not observed in the bloodstream of MBT mice (Fig. 7a).
The initial tethering and rolling of circulating leukocytes mediated by PSGL-1 precedes firm attachment 
needed for leukocyte arrest before extravasation. Firm attachment has been suggested to be facilitated by leuko-
cyte activation and PSGL-1 downregulation32. Upon activation by a variety of stimuli, the expression of PSGL-1 
on the surface of circulating leukocytes decreases32–34. We assayed leukocytes that expressed PSGL-1 on days 0 to 
3 after infection in BALB/c and MBT blood. Figure 7b shows that, at day 1 post infection, PSGL-1-positive leuko-
cyte levels were higher in BALB/c than in MBT blood suggesting greater tethering ability of BALB/c leukocytes 
at this early stage. Interestingly from that moment onwards, PSGL-1-positive leukocyte levels declined gradually 
in BALB/c blood suggesting that activation of circulating leukocytes started on day 1 post infection in BALB/c 
mice. By contrast, in MBT blood, the highest levels of PSGL-1-positive leukocytes were observed on day 2 post 
infection, that was also the time when the levels of PSGL-1-positive leukocytes began to decrease. These data 
Figure 6. Greater IFN-α expression, but weaker IFNAR1 expression in MBT mice. (a) Serum IFN-α 
concentrations in BALB/c and MBT mice on days 0–3 post infection (n = 8 per strain, infected, n = 3 per strain, 
sham-infected). (b) Percentages of total IFNAR1-positive leukocytes in the blood, spleen, and liver of BALB/c 
and MBT mice as measured by flow cytometry. Cytometry experiments were performed twice (n = 5 mice/
strain/timepoint). Representative experiments are displayed. Data are represented as mean ± SEM. Two-way 
ANOVA was used to test differences between means. *P values < 0.05, **P < 0.01, and ***P < 0.001.
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suggest delayed activation of circulating leukocytes in MBT mice. These results suggest that RVFV induces earlier 
activation of circulating leukocytes in BALB/c mice.
Discussion
MBT mice survive after infection with West Nile virus or influenza A virus in conditions where BALB/c mice die. 
However, after inoculation with RVFV, MBT mice died at a median of 3 days, with histological and biochemical 
signs of acute hepatitis, while BALB/c mice survived up to a week longer. An increase in splenic neutrophils 
on day 2 post infection suggests an earlier inflammatory response in MBT mice. This is in line with the higher 
IFN-α concentration in MBT serum on day 2 post infection. However, despite the protection normally conferred 
by IFN-α, MBT mice had a rapid rise in viral antigen load, suffered from hepatitis, and eventually died. In fact, 
MBT mice display several immune-related defects. Notable amongst those are the levels of leukocytes expressing 
IFNAR1 which were lower in the blood, spleen, and liver of MBT mice than in BALB/c mice. IFNAR1 is crucial 
in engaging innate cell machinery to restrict viral spread, and in expanding sufficient leukocyte numbers to tackle 
intracellular infection. Signaling through receptor type I IFNs induces hundreds of genes to establish an antiviral 
state35. Although RVFV-infected MBT mice produced serum IFN-α, their lower percentage of IFNAR1-positive 
leukocytes compared to BALB/c mice suggests a weakened type I IFN response in MBT mice. Lack of IFNAR1 
expression in subsets of myeloid cells has been shown to enhance West Nile virus infection and tissue injury in 
visceral organs, including the liver36. Thus, decreased percentage of leukocytes expressing IFNAR1 likely contrib-
utes to the susceptible MBT phenotype.
Recruitment of circulating leukocytes from blood to infected tissues is a crucial component of host defense 
mechanisms. P-selectin glycoprotein ligand-1 (PSGL-1) is the primary ligand for P-selectin. PSGL-1 is consti-
tutively expressed on the surface of circulating leukocytes while P-selectin is expressed by endothelial cells24, 37. 
Activation of circulating leukocytes is associated with decreased surface expression of PSGL-1. This 
down-regulation decreases leukocyte adhesion to P-selectin expressed by the vascular endothelium thus favoring 
the transition from weak selectin-mediated interaction to firm attachment via the β2 integrins and ICAM-132, 38. 
We have shown that, following infection, circulating leukocytes exhibited a delayed down-regulation of PSGL-1 
in MBT mice compared to BALB/c mice.
IFN-γ is a pro-inflammatory mediator produced in response to intracellular pathogens39. IFN-γ has been 
shown to reduce viremia, thus eliminating clinical signs in RVFV-infected rhesus monkeys40. IFN-γ also serves 
as an activation marker. We have observed that the levels of circulating leukocytes that produced IFN-γ 3 days 
after infection were low in MBT mice compared to BALB/c mice. These observations can be explained in several 
ways. First, circulating MBT leukocytes failed to express IFN-γ as a result of poorly efficient or delayed activation 
despite a higher viral antigen load in the blood. This hypothesis is supported by the delayed down-regulation 
of PSGL-1 seen in circulating MBT leukocytes. Second, in MBT mice, activated (IFN-γ-positive) leukocytes 
migrated to the liver where the viral antigen load was the highest, and were therefore lacking in the blood. Both 
mechanisms can contribute independently to the weak levels of IFN-γ-positive leukocytes in the blood of MBT 
mice.
LDA analysis on immune cell subsets ranked neutrophil level as the major variable discriminating infected 
BALB/c and MBT mice at day 3 post infection. Circulating neutrophils were indeed at low levels in RVFV-infected 
MBT mice, and the capacity to replenish this population was reduced compared to BALB/c mice. It has previ-
ously been shown that neutropenia can contribute to susceptibility to viral infections, for example, in the case 
of Simian Immunodeficiency Virus (SIV) infections of nonhuman primates41 (reviewed in ref. 42). However, we 
have shown that C57BL/6 mice homozygous for either Gfi1Gen or GfiGFP, two alleles associated with severe neutro-
penia, were not more susceptible than wild type C57BL/6 mice, suggesting that low number of neutrophils does 
not worsen RVF disease. Therefore, it is likely that the neutropenia observed in infected MBT mice is the result 
of the pathogenesis associated with RVFV infection rather than a major causal component of the susceptibility. 
Figure 7. Delayed activation of circulating leukocytes in MBT mice. (a) Percentages of circulating leukocytes 
expressing IFN-γ in BALB/c and MBT mice on days 1–3 post infection as evaluated by intracellular flow 
cytometry. (b) Percentages of PSGL-1-positive circulating leukocytes in BALB/c and MBT mice on days 
0–3 post infection. Cytometry experiments were performed twice (n = 5 mice/strain/timepoint). Data are 
represented as mean ± SEM. Representative experiments are displayed. Two-way ANOVA was used to test 
differences between means. *P < 0.05, **P < 0.01, and ***P < 0.001.
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A second non-mutually exclusive possibility is that neutropenia impinges negatively on health status in the MBT 
genetic background only.
Altogether, the results presented in this paper show that despite an earlier inflammatory response, MBT sus-
ceptible mice are unable to mount and maintain an adequate response against RVFV. Our study thus provides 
novel evidence for understanding the links and markers of pathogenesis of variable disease progression between 
infected individuals, and the analysis of the complex genetic component of susceptibility to RVF disease.
Materials and Methods
Mice, virus, infection and tissue harvest. Experiments on live mice were conducted according to the 
French and European regulations on care and protection of laboratory animals (EC Directive 2010/63/UE and 
French Law 2013-118 issued on February 1, 2013). Experimental protocols were approved by the Animal Ethics 
Committee of Institut Pasteur (N° 89). All experiments that involved virulent RVFV were performed in the 
biosafety level 3 (BSL3) facilities of the Institut Pasteur, and carried out in compliance with the recommendations 
of the Institut Pasteur Biosafety Committee (N° 14.320).
BALB/cByJ, MBT/Pas, PWK/Pas, SEG/Pas, 129/SvPas, C57BL/6 J, Gfi1GFP/GFP and Gfi1+/GFP C57BL/6 mice 
were bred and maintained at Institut Pasteur23, 27, 43–45. Gfi1Gen/Gen and Gfi1+/+ C57BL/6 controls were obtained 
from Centre d’Immunologie de Marseille-Luminy (Marseille, France)28. All studies used RVFV strain ZH548, 
obtained from Centre National de Référence des Fièvres Hémorragiques Virales (Institut Pasteur, Lyon, France)46, 47. 
Because sex influences the severity of infection12, only male mice were used. Approximately 102 PFU of ZH548 
RVFV were injected intraperitoneally into 9–14 week-old BALB/c and MBT mice11. Infected mice were mon-
itored daily for clinical symptoms. Clinical scores included no symptoms, mild lethargy (slow gait), paralysis 
or neurological displays (spinning and/or head-tilting), and severe lethargy (a combination of slow gait and 
decreased response time to stimulus). Mice were provided with water and wet chow when paralyzed, and euth-
anized when moribund. Mice that survived until day 15 post infection were also euthanized. Blood was taken 
by cardiac puncture, while femur bone marrow, brain, liver and spleen were removed by manual dissection. 
Bone marrow from the left and right femur was collected by quick centrifugation of bone in a perforated 0.5 ml 
Eppendorf tube placed into a 1.5 ml Eppendorf tube supplied with 200 μl of Dulbeccos’s Phosphate Buffered 
Saline (PBS). Entire organs were processed for flow cytometric analysis and histology.
IFN-α and IFN-β Measurements. Blood was collected by cardiac puncture from mock- (n = 3 per strain) 
and RVFV-infected (n = 8 per strain) MBT and BALB/c mice. IFN-α and IFN-β were assayed using the mouse 
IFN-α and IFN-β ELISA kits (PBL Biomedical Laboratories, Piscataway, NJ). The kits’ lower limits of quantifica-
tion were 12.5 and 15.6 pg/ml for IFN-α and IFN-β, respectively.
Liver Enzymes Measurement. Blood was collected from mock- (n = 3 per strain) and RVFV-infected 
(n = 9 per strain) MBT and BALB/c mice by cardiac puncture. Sera were analyzed on a VetTest chemistry analyzer 
(IDEXX laboratories, Westbrook, ME) to determine alanine aminotransferase (ALT) and aspartate transaminase 
(AST) levels.
Histopathology. For histological analysis, whole liver (n = 7 per strain) was fixed for one week in 10% 
neutral-buffered formalin, then immersed for 24 hrs in 70% ethanol. Samples from four representative areas of 
each lobe were embedded in paraffin, and 5 μm-thick sections were cut and stained with hematoxylin and eosin 
(HE). Slides were visualized with the Histofine Simple Stain MAX-PO kit (Nichorei Biosciences Inc., Tokyo, 
Japan). The histological characterization of liver lesions was completed by an immunohistochemical detection 
of the RVFV using mouse antibodies against the N protein of RVFV (dilution 1:100). Sections were analyzed 
in a blind study on coded slides to evaluate the histological architecture and to identify presence of virus and 
neutrophils.
Flow Cytometry Analysis. Mice (n = 5 per strain/3 independent experiments) were transcardially perfused 
with PBS until liver blanched. Entire organs were harvested in Hank’s Balanced Salt Solution (HBSS). Single-cell 
suspensions were prepared after mechanical disruption with the gentleMACS Dissociator (Miltenyi Biotec, San 
Diego, CA). Liver was exposed to a first dissociation cycle, and incubated at 37 °C for 20 min with 100 IU/ml 
collagenase IV (Worthington, Lakewood, NJ) in HBSS before a second cell disruption cycle. Cell suspensions 
from liver and brain were filtered through a 40 μM cell strainer, and purified by Ficoll-Paque density gradi-
ent (GE Healthcare Life Sciences, Marlborough, MA). Cell suspensions were treated with red blood cell lysis 
buffer (Miltenyi Biotec SAS), diluted to 1–8 million cells/ml, incubated with the mouse 2.4G2 FcyII blocker (BD 
Biosciences, San Jose, CA), stained for surface markers over a 1 hr incubation period, fixed in 4% PFA solution, 
and resuspended in albumin 2% in PBS (PAN-Biotech, Aidenbach, Germany). Antibodies used for staining are 
listed in Supplementary Table 1. For intracellular staining, cells were treated with a permeabilization buffer (eBi-
oscience, San Diego, CA) before a 90 min staining incubation. Leukocytes were classified as CD45+; neutrophils 
were identified as CD45+ Ly6C/6 G+; NK cells as CD45+ CD335+; macrophages as CD4+ CD11b+ CD11c−; 
B-cells as CD45+ CD19+; cytotoxic T-cells as CD45+ CD3e+ CD8+; helper T-cells as CD45+ CD3e+ CD4+; 
and conventional dendritic cells (DCs) as CD45+, CD1b+, CD11c+. PSGL-1 and IFNAR1 were assessed by sur-
face staining antibodies. Caspase-3 and IFN-γ were measured post surface staining by the intracellular staining 
protocol. Fluorescence was measured using a four-laser LSRII flow cytometer (BD Biosciences). For each samples 
a total number of at least 200,000 cells was analyzed. Dead cells were visualized using eFluor 780 (eBioscience) 
(For example of typical gating scheme see Supplementary Fig. 7). When cell populations did not stain to generate 
two clearly distinct populations, gates were drawn to isolate the majority of all positive cell populations, and the 
gates were applied to experimental and control samples alike. Gating was determined by both single-stained 
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control, and fluorescence minus one control. Data analysis was performed using FlowJo software version 10 
(Ashland, OR).
Thioglycollate Neutrophil Migration. Peritonitis was induced by intraperitoneal injection of 1 ml sterile 
thioglycollate 3% in PBS (Sigma-Aldrich, St. Louis, MO) into naive BALB/c and MBT mice (n = 5 per strain/2 
independent experiments). In parallel BALB/c and MBT mice were injected 1 ml PBS, as a control. Peritoneal 
cavities were washed with 2 × 5 ml of ice-cold sterile PBS, and the cells were subsequently centrifuged and resus-
pended for flow cytometry analysis.
Statistical Analysis. Measurements were carried out on individual mice, and the mean and standard error 
of mean (SEM) were calculated for each mouse strain. Mantel-Cox’s Logrank test was applied to assess sur-
vival curve differences. Two-way ANOVA was used to compare percentages of innate immune cells, cell viability, 
N-ag-, IFN-γ-positive cells, and IFN-α levels during infection. Mann-Whitney U test was used to analyze levels 
of liver enzymes. PCA and LDA analyses were performed with R software version 3.0.048. All other analyses were 
performed with Prism 6.02 (GraphPad, San Diego, CA). Significance was considered for P values < 0.05 (*), but 
included P values < 0.01 (**), and < 0.001 (***) as indicated.
Data Availability. All data generated or analyzed during this study are included in this published article (and 
its Supplementary Information files).
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